The Impact of Patient Travel Time on Disparities in Treatment for Early Stage Lung Cancer in California

Citation

Obrochta, Chelsea A.; Parada, Humberto Jr.; Murphy, James D.; Nara, Atsushi; Trinidad, Dennis; Araneta, Maria Rosario H.; & Thompson, Caroline A. (2022). The Impact of Patient Travel Time on Disparities in Treatment for Early Stage Lung Cancer in California. PLOS ONE, 17(10), e0272076. PMCID: PMC9534452

Abstract

BACKGROUND: Travel time to treatment facilities may impede the receipt of guideline-concordant treatment (GCT) among patients diagnosed with early-stage non-small cell lung cancer (ES-NSCLC). We investigated the relative contribution of travel time in the receipt of GCT among ES-NSCLC patients.
METHODS: We included 22,821 ES-NSCLC patients diagnosed in California from 2006-2015. GCT was defined using the 2016 National Comprehensive Cancer Network guidelines, and delayed treatment was defined as treatment initiation >6 versus

URL

http://dx.doi.org/10.1371/journal.pone.0272076

Reference Type

Journal Article

Year Published

2022

Journal Title

PLOS ONE

Author(s)

Obrochta, Chelsea A.
Parada, Humberto Jr.
Murphy, James D.
Nara, Atsushi
Trinidad, Dennis
Araneta, Maria Rosario H.
Thompson, Caroline A.

Article Type

Regular

PMCID

PMC9534452

Data Set/Study

California Cancer Registry (CCR)

Continent/Country

United States

State

California

Race/Ethnicity

White
Black
Asian
Hispanic

ORCiD

Thompson, C. - 0000-0001-9990-9756